A simple blood test can show early who is beating lung cancer

If you or someone you love is facing lung cancer, here is a hopeful result. A simple blood draw, taken during treatment before surgery, can show early who is responding well. People whose blood test came back clean stayed cancer-free much longer.

This might sound like something only doctors need to know. It is not. It is a tool you can ask about, and it points toward a future where patients get answers sooner and treatment fits each person better.

How the study worked

The NeoCOAST-2 trial followed people with stage IIA to IIIB non-small cell lung cancer that could be removed by surgery. Everyone got standard chemotherapy plus an immunotherapy drug called durvalumab before surgery, and each person also received one of three experimental drugs, in groups of 54 to 76 people. The results were published Oct. 25, 2026, in Nature. The groups were small and not built to be compared head to head, and the link between blood results and outcomes came from a follow-up analysis, so larger trials will confirm the details.

What is ctDNA, in plain words?

Tumors shed tiny bits of their DNA into the bloodstream. Doctors call this circulating tumor DNA, or ctDNA. A blood test can measure it, so it works like a signal showing how much cancer is still active. When the signal drops to zero, doctors call it “clearance.”

What they found

The researchers checked the blood at the start of the third treatment cycle, before surgery. In the group that received the drug datopotamab deruxtecan (Dato-DXd), the tumor DNA cleared in 72.5% of people, nearly three in four. In the other two groups, it cleared in 50.9% (oleclumab) and 54.5% (monalizumab), about half.

The Dato-DXd group also led on the other measures. At surgery, 35.2% of that group had no cancer left in the removed tissue, about one in three. The other two groups had 20.3% and 25.7%. Two years out, 77.9% of the Dato-DXd group had stayed free of cancer events, compared with 70.5% and 75.7%.

The blood test also told a clear story about the future. Across all three groups, people whose tumor DNA cleared stayed cancer-free much longer than people whose tumor DNA did not clear. The difference was large, and it was very unlikely to be chance.

The best news came from combining two signals. People who had both a clean blood test and no cancer left at surgery did best of all. Their time cancer-free was far longer than that of people with neither.

The researchers say that looking at both signals together could help doctors sort out who is doing well and who needs a closer look. They also say the Dato-DXd combination had the highest numbers and deserves further study.

What you can do today

If you or someone close to you has lung cancer that can be removed by surgery, bring one question to the next appointment: “Could a ctDNA blood test help guide my treatment?” You can also ask whether a clinical trial is a good fit. The trial in this story is listed on ClinicalTrials.gov under NCT05061550, and the site lets you search for studies near you.

Write the question in your phone notes or on a card today, so it is ready when you need it.